文献速递临床试验与 GCP流行病学与生物统计

无发热男性尿路感染7天与14天抗生素疗程对比:随机临床试验

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机双盲安慰剂对照非劣效试验纳入272例无发热男性尿路感染患者,比较环丙沙星或复方磺胺甲噁唑7天与14天疗程。结果显示7天疗程在停药后14天症状缓解率方面非劣效于14天疗程,支持将7天疗程作为替代方案。

要点

  • 7天疗程症状缓解率93.1%,14天疗程90.2%,差异2.9%符合非劣效界值。
  • 7天疗程复发率9.9%,14天疗程12.9%,差异无统计学意义。
  • 无发热男性尿路感染可采用7天环丙沙星或复方磺胺甲噁唑疗程。

核心结论

  • 在无发热男性尿路感染患者中,环丙沙星或复方磺胺甲噁唑7天疗程在停药后14天症状缓解方面非劣效于14天疗程。

研究设计与样本

  • 随机、双盲、安慰剂对照非劣效试验,在美国2个退伍军人事务医疗中心进行,2014年4月至2019年12月入组,最终随访2020年1月28日。
  • 1058例符合条件男性中272例随机分配,7天组136例,14天组136例,疗程第8至14天分别接受继续抗生素或安慰剂。
  • 主要分析采用符合方案人群(服用至少26/28剂且未连续漏服超过2剂),次要分析包括所有随机患者。

主要发现

  • 符合方案分析中,7天组症状缓解122/131(93.1%),14天组111/123(90.2%),差异2.9%(单侧97.5%CI,-5.2%至∞),满足非劣效标准。
  • 随机化分析中,7天组症状缓解125/136(91.9%),14天组123/136(90.4%),差异1.5%(单侧97.5%CI,-5.8%至∞)。
  • 不良事件:7天组28/136(20.6%),14天组33/136(24.3%)。

关键数值与推荐

  • 非劣效界值设定为10%。
  • 主要终点为完成有效抗生素治疗后14天内尿路感染症状缓解。

临床怎么用

  • 对于无发热男性疑似尿路感染,可考虑使用环丙沙星或复方磺胺甲噁唑7天疗程替代14天疗程。

局限性

  • 研究仅纳入无发热男性退伍军人,结论外推需谨慎。
  • 主要分析基于符合方案人群,可能存在依从性偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Determination of optimal treatment durations for common infectious diseases is an important strategy to preserve antibiotic effectiveness. OBJECTIVE: To determine whether 7 days of treatment is noninferior to 14 days when using ciprofloxacin or trimethoprim/sulfamethoxazole to treat urinary tract infection (UTI) in afebrile men. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled noninferiority trial of afebrile men with presumed symptomatic UTI treated with ciprofloxacin or trimethoprim/sulfamethoxazole at 2 US Veterans Affairs medical centers (enrollment, April 2014 through December 2019; final follow-up, January 28, 2020). Of 1058 eligible men, 272 were randomized. INTERVENTIONS: Participants continued the antibiotic prescribed by their treating clinician for 7 days of treatment and were randomized to receive continued antibiotic therapy (n = 136) or placebo (n = 136) for days 8 to 14 of treatment. MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was resolution of UTI symptoms by 14 days after completion of active antibiotic treatment. A noninferiority margin of 10% was selected. The as-treated population (participants who took ≥26 of 28 doses and missed no more than 2 consecutive doses) was used for the primary analysis, and a secondary analysis included all patients as randomized, regardless of treatment adherence. Secondary outcomes included recurrence of UTI symptoms and/or adverse events within 28 days of stopping study medication. RESULTS: Among 272 patients (median [interquartile range] age, 69 [62-73] years) who were randomized, 100% completed the trial and 254 (93.4%) were included in the primary as-treated analysis. Symptom resolution occurred in 122/131 (93.1%) participants in the 7-day group vs 111/123 (90.2%) in the 14-day group (difference, 2.9% [1-sided 97.5% CI, -5.2% to ∞]), meeting the noninferiority criterion. In the secondary as-randomized analysis, symptom resolution occurred in 125/136 (91.9%) participants in the 7-day group vs 123/136 (90.4%) in the 14-day group (difference, 1.5% [1-sided 97.5% CI, -5.8% to ∞]) Recurrence of UTI symptoms occurred in 13/131 (9.9%) participants in the 7-day group vs 15/123 (12.9%) in the 14-day group (difference, -3.0% [95% CI, -10.8% to 6.2%]; P = .70). Adverse events occurred in 28/136 (20.6%) participants in the 7-day group vs 33/136 (24.3%) in the 14-day group. CONCLUSIONS AND RELEVANCE: Among afebrile men with suspected UTI, treatment with ciprofloxacin or trimethoprim/sulfamethoxazole for 7 days was noninferior to 14 days of treatment with regard to resolution of UTI symptoms by 14 days after antibiotic therapy. The findings support the use of a 7-day course of ciprofloxacin or trimethoprim/sulfamethoxazole as an alternative to a 14-day course for treatment of afebrile men with UTI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01994538.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Drekonja DM, Trautner B, Amundson C, et al. Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. JAMA. 2021. PMID: 34313686. doi:10.1001/jama.2021.9899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。